Xiong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiong Chen has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Xiuping Yang
Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China; Sleep Medicine Centre, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
17 shared publicationsWeisong Cai
Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
14 shared publicationsXiaoping Ming
Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
13 shared publicationsBaoai Han
Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
10 shared publicationsYifan Hu
Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
9 shared publicationsZehua Lin
9 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (12) , 8269
Correction: Assessing the application potential of different species as obstructive sleep apnea models: a comparative analysis based on cranial CT anatomy
- 13 October 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (12) , 8269
Open AccessCorrection: Assessing the application potential of different species as obstructive sleep apnea models: a comparative analysis based on cranial CT anatomy
- 30 August 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 8905-8925
Multi-omics, machine learning, and molecular simulation identify CD44 as a candidate target in endocrine-disrupting chemical–associated thyroid cancer progression
- 30 August 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 8905-8925
Multi-omics, machine learning, and molecular simulation identify CD44 as a candidate target in endocrine-disrupting chemical–associated thyroid cancer progression
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Supplementary Figure S2. The MTHFD2 inhibitor DS18561882 impairs proliferation and migration of TSCC cells.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Supplementary Figure S2. The MTHFD2 inhibitor DS18561882 impairs proliferation and migration of TSCC cells.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
The list of TSCC patient cases from the TCGA-HNSC project used for the Kaplan-Meier survival analysis is provided in Supplementary File Table 2
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
The list of TSCC patient cases from the TCGA-HNSC project used for the Kaplan-Meier survival analysis is provided in Supplementary File Table 2
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a pivotal enzyme in one-carbon metabolism, is significantly overexpressed in tongue squamous cell carcinoma (TSCC) and correlates with poor patient prognosis. Functional studies demonstrate that MTHFD2 drives TSCC proliferation and migration in vitro and in vivo, whereas its inhibition suppresses tumor progression. Mechanistically, MTHFD2 orchestrates a dual posttranslational modification cascade: Through its enzymatic activity, it simultaneously induces forkhead box O1 (FOXO1) hypermethylation and ubiquitination, ultimately triggering ubiquitin–proteasome degradation of this tumor suppressor. This methylation-primed degradation axis is clinically validated by the inverse MTHFD2-high/FOXO1-low expression pattern in TSCC specimens, which predicts adverse outcomes. Critically, pharmacologic inhibition of MTHFD2 (e.g., DS18561882) blocks FOXO1 degradation, establishing the MTHFD2–FOXO1 axis as a promising therapeutic target for TSCC through its novel metabolic–epigenetic regulatory mechanism.Implications:This study identifies the MTHFD2–FOXO1 axis as a druggable metabolic–epigenetic pathway in TSCC, providing both a prognostic marker and a therapeutic target.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a pivotal enzyme in one-carbon metabolism, is significantly overexpressed in tongue squamous cell carcinoma (TSCC) and correlates with poor patient prognosis. Functional studies demonstrate that MTHFD2 drives TSCC proliferation and migration in vitro and in vivo, whereas its inhibition suppresses tumor progression. Mechanistically, MTHFD2 orchestrates a dual posttranslational modification cascade: Through its enzymatic activity, it simultaneously induces forkhead box O1 (FOXO1) hypermethylation and ubiquitination, ultimately triggering ubiquitin–proteasome degradation of this tumor suppressor. This methylation-primed degradation axis is clinically validated by the inverse MTHFD2-high/FOXO1-low expression pattern in TSCC specimens, which predicts adverse outcomes. Critically, pharmacologic inhibition of MTHFD2 (e.g., DS18561882) blocks FOXO1 degradation, establishing the MTHFD2–FOXO1 axis as a promising therapeutic target for TSCC through its novel metabolic–epigenetic regulatory mechanism.Implications:This study identifies the MTHFD2–FOXO1 axis as a druggable metabolic–epigenetic pathway in TSCC, providing both a prognostic marker and a therapeutic target.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Supplementary Figures S1. Prognostic value of gene expression levels in TSCC patients.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Supplementary Figures S1. Prognostic value of gene expression levels in TSCC patients.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
A complete list of experimental reagents and resources is included in Supplementary Table 1.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
A complete list of experimental reagents and resources is included in Supplementary Table 1.
- Open Access
- 16 June 2026
- Published by Elsevier in SSRN Electronic Journal
Based on Network Pharmacology and Experimental Validation of β-Sitosterol Alleviates Cisplatin-Induced Hearing Loss via Phosphorylated MAPK3
PurposeThis research aimed to investigate the protective role as well as molecular mechanisms of Rehmanniae Radix Praeparata and its bioactive compound β-sitosterol in preventing CIHL.MethodsNetwork pharmacology and bioinformatic analyses were used to identify the pharmacologically active constituents of Rehmanniae Radix Praeparata and predict their potential molecular targets. The influence of β-sitosterol on hair cell damage, apoptosis, reactive oxygen species (ROS) levels, and target protein expression were evaluated in vitro as well as in vivo.ResultsThe primary active constituents of Rehmanniae Radix Praeparata were β-sitosterol and stigmasterol. They shared 50 potential targets with CIHL, with MAPK3, SRC, and ESR1 as the top three. Molecular docking combined with dynamics simulations demonstrated strong binding and stable complex formation between β-sitosterol and MAPK3. In vitro, β-sitosterol mitigated cisplatin-induced hair cell death, reduced ROS levels, and restored phosphorylated MAPK3. In vivo, it enhanced hearing, decreased hair cell loss, and partially restored phosphorylated MAPK3 in the cochleae of cisplatin-treated mice.ConclusionRehmanniae Radix Praeparata and its active component β-sitosterol protected cochlear hair cells from cisplatin-induced damage by restoring MAPK3 phosphorylation signaling pathway, providing new molecular targets and strategies for CIHL treatment.
- 16 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBased on Network Pharmacology and Experimental Validation of β-Sitosterol Alleviates Cisplatin-Induced Hearing Loss via Phosphorylated MAPK3
PurposeThis research aimed to investigate the protective role as well as molecular mechanisms of Rehmanniae Radix Praeparata and its bioactive compound β-sitosterol in preventing CIHL.MethodsNetwork pharmacology and bioinformatic analyses were used to identify the pharmacologically active constituents of Rehmanniae Radix Praeparata and predict their potential molecular targets. The influence of β-sitosterol on hair cell damage, apoptosis, reactive oxygen species (ROS) levels, and target protein expression were evaluated in vitro as well as in vivo.ResultsThe primary active constituents of Rehmanniae Radix Praeparata were β-sitosterol and stigmasterol. They shared 50 potential targets with CIHL, with MAPK3, SRC, and ESR1 as the top three. Molecular docking combined with dynamics simulations demonstrated strong binding and stable complex formation between β-sitosterol and MAPK3. In vitro, β-sitosterol mitigated cisplatin-induced hair cell death, reduced ROS levels, and restored phosphorylated MAPK3. In vivo, it enhanced hearing, decreased hair cell loss, and partially restored phosphorylated MAPK3 in the cochleae of cisplatin-treated mice.ConclusionRehmanniae Radix Praeparata and its active component β-sitosterol protected cochlear hair cells from cisplatin-induced damage by restoring MAPK3 phosphorylation signaling pathway, providing new molecular targets and strategies for CIHL treatment.
- 19 April 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 8595-8610
Multi-omics, molecular modeling and experimental analysis of carcinogen benzo(a)pyrene promoting the progression of laryngeal cancer
- 19 April 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 8595-8610
Multi-omics, molecular modeling and experimental analysis of carcinogen benzo(a)pyrene promoting the progression of laryngeal cancer